Accustem Sciences Inc. (ACUT)

OTCMKTS: ACUT · Delayed Price · USD
0.645
+0.035 (5.74%)
Feb 20, 2024, 10:48 AM EST - Market closed
Market Cap 7.32M
Revenue (ttm) n/a
Net Income (ttm) -681.45M
Shares Out 11.35M
EPS (ttm) -61.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,055
Open 0.580
Previous Close 0.610
Day's Range 0.510 - 0.645
52-Week Range 0.450 - 1.950
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ACUT

AccuStem Sciences, Inc., an early-stage life sciences company, focuses on developing and commercializing products for the treatment and management of various cancers. The company's genomics-based personalized medicine business primarily focuses on breast and lung cancer patients. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was founded in 2013 and is headquartered in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 4
Stock Exchange OTCMKTS
Ticker Symbol ACUT
Full Company Profile

Financial Performance

Financial Statements

News

AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership

LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and Emeritus...

7 months ago - GlobeNewsWire

AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer

LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs furthe...

8 months ago - GlobeNewsWire

Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc.

BALTIMORE, MD / ACCESSWIRE / June 20, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new re...

8 months ago - Accesswire

AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals

LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today...

9 months ago - GlobeNewsWire

AccuStem Announce Strategic Clinical and Operational Partnership

LONDON and PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announc...

9 months ago - GlobeNewsWire

AccuStem Sciences Announces Extension of its US Patent Application for SPARE Test for Patients with Breast Cancer

LONDON and PHOENIX, May 02, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced tod...

10 months ago - GlobeNewsWire

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

LONDON and PHOENIX, Dec. 06, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairm...

1 year ago - GlobeNewsWire

AccuStem Sciences Announces Appointment of Sean McDonald to Board of Directors

LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced to...

1 year ago - GlobeNewsWire

AccuStem Announces Adjournment of Annual Meeting of Stockholders

LONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced tod...

1 year ago - GlobeNewsWire

AccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients with Breast Cancer

LONDON and PHOENIX, Ariz., Sept. 13, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, anno...

1 year ago - GlobeNewsWire

AccuStem Sciences, Inc. Announces DTC Eligibility

LONDON and PHOENIX, April 14, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce i...

2 years ago - GlobeNewsWire

AccuStem Announces Private Placement of Common Stock

LONDON and PHOENIX, April 05, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that it has...

2 years ago - GlobeNewsWire

AccuStem Sciences, Inc. Appoints New Executive Leadership Team

Company plans to uplist to the Nasdaq Capital Market Company plans to uplist to the Nasdaq Capital Market

2 years ago - GlobeNewsWire